Lombard Odier Asset Management (Switzerland)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-155,411	Closed	-$15.1M	–	177
2023 Q1	$15.1M	Sell	155,411 -50,802	-25%	-$5.27M	1.32%	21
2022 Q4	$21.3M	Sell	206,213 -16,725	-8%	-$1.57M	1.71%	10
2022 Q3	$18.9M	Sell	222,938 -27,579	-11%	-$2.46M	1.6%	16
2022 Q2	$20.8M	Sell	250,517 -41,353	-14%	-$3.29M	1.76%	15
2022 Q1	$22.5M	Buy	+291,870	New	+$24.4M	1.77%	21
2016 Q2	–	Sell	-674	Closed	-$56K	–	308
2016 Q1	$56K	Hold	674	–	–	0.01%	392
2015 Q4	$71K	Buy	+674	New	+$70.4K	0.01%	403
2014 Q4	–	Sell	-108,400	Closed	-$7.83M	–	436
2014 Q3	$7.83M	Buy	+108,400	New	+$7.12M	0.2%	130

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s BMRN Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 155,411 shares — an estimated $15.1M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in BMRN in Q3 2014 and held it in 8 quarters. The position peaked at $22.5M in Q1 2022. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 155,411 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $15.1M.
Lombard Odier Asset Management (Switzerland) first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 8 quarters.
Lombard Odier Asset Management (Switzerland)'s BioMarin Pharmaceuticals position peaked at $22.5M in Q1 2022.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.